Regulus Therapeutics Inc. (RGLS) Lifted to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) from a hold rating to a buy rating in a research report report published on Tuesday. They currently have $1.50 price objective on the biopharmaceutical company’s stock.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

Several other equities research analysts also recently commented on the stock. Wedbush reiterated an ourperform rating and set a $6.00 target price on shares of Regulus Therapeutics in a research report on Tuesday, June 13th. BMO Capital Markets set a $1.00 target price on shares of Regulus Therapeutics and gave the stock a hold rating in a research report on Monday, June 12th. Chardan Capital cut their target price on shares of Regulus Therapeutics from $5.00 to $2.50 and set a buy rating on the stock in a research report on Tuesday, June 13th. Finally, Needham & Company LLC reiterated a hold rating on shares of Regulus Therapeutics in a research report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $3.67.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2958134/regulus-therapeutics-inc-rgls-lifted-to-buy-at-zacks-investment-research.html.

In other news, Director William H. Rastetter purchased 274,725 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were purchased at an average price of $0.91 per share, for a total transaction of $249,999.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Joseph P. Hagan purchased 219,780 shares of the company’s stock in a transaction dated Tuesday, July 25th. The stock was purchased at an average price of $0.91 per share, for a total transaction of $199,999.80. Following the transaction, the insider now directly owns 241,297 shares in the company, valued at approximately $219,580.27. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 549,450 shares of company stock worth $500,000. 4.80% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC lifted its position in shares of Regulus Therapeutics by 0.5% in the 2nd quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock worth $7,862,000 after purchasing an additional 37,489 shares during the period. EcoR1 Capital LLC lifted its position in shares of Regulus Therapeutics by 145.6% in the 2nd quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock worth $3,656,000 after purchasing an additional 2,199,144 shares during the period. Wells Fargo & Company MN lifted its position in shares of Regulus Therapeutics by 13.5% in the 1st quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after purchasing an additional 93,295 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Regulus Therapeutics by 189.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 240,890 shares during the period. Finally, Wedbush Securities Inc. lifted its position in shares of Regulus Therapeutics by 10.3% in the 2nd quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock worth $197,000 after purchasing an additional 18,600 shares during the period. Hedge funds and other institutional investors own 21.94% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.